AML is an aggressive hematologic malignancy where molecular characterization can be time-sensitive in research settings for operational workflow and investigational assessment. The oncoReveal Rapid ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
Flow cytometry–triggered genomic testing and automation reduced turnaround times for AML diagnostics, enhancing personalized therapy and patient care. The initiative involved clinician education, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results